News | November 14, 2022
Biocon Biologics features on ASIA IP ELITE List 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated
